ABG Sundal Collier acted as Joint Bookrunner in the IPO of Cinclus Pharma on Nasdaq Stockholm

On 20 June 2024, Cinclus Pharma AB (“Cinclus Pharma” or the “Company”), the clinical stage pharmaceutical company, successfully completed its initial public offering on the Nasdaq Stockholm Main Market (the “IPO”). The IPO consisted of a primary offering of SEK 787m, including the over-allotment option, and attracted strong interest from Swedish and international institutional investors as well as the general public in Sweden.
Trill Impact Ventures Pharma 1 AB, the Fourth Swedish National Pension Fund, Linc AB, a number of investors that are shareholders in Regulus Pharma Fas I AB, Eir Ventures I AB and Irrus Investments Nominee Ltd acted as cornerstone investors in the IPO. The IPO was priced at SEK 42 per share, which corresponds to a market value of all outstanding shares of approximately SEK 2 billion following the completion of the IPO, including the over-allotment option. Trading commenced on 20 June 2024 on Nasdaq Stockholm under the ticker CINPHA.
ABGSC acted as Joint Bookrunner in the IPO and would like to express its gratitude to Cinclus Pharma for the vote of confidence.